Satellite Symposia and Product Theaters

THSNA is happy to present the 2018 Satellite Symposium Program. Please note the following:

  • Each event is planned independently of the THSNA program committee and THSNA does not endorse the programming content.
  • You must be a THSNA registrant in order to attend any satellite symposia.
  • There is no cost to attend these symposia.
  • All symposia occur during a meal and food will be provided.
  • If a pre-registration link is not provided, all admittance will be on a first-come, first-served basis.
  • Any pre-registrants not present at the session room door 10 minutes prior to the start of the program will be removed from the pre-registrant list.
  •  

Thursday, March 8th


Fundamental Factors: Challenging Hypotheses in Hemophilia Treatment

Sponsored By: Bioverativ

12:00 PM - 2:00 PM, Marriott Grand Ballroom 1 & 2

Is it time to improve conventional wisdom about how we treat patients and evaluate outcomes in hemophilia? As the market continues to change and new therapies emerge, new clinical questions also arise.

To help make sense of these changes, Bioverativ® is pleased to gather an expert panel of your peers for Fundamental Factors: Challenging Hypotheses in Hemophilia Treatment. This symposium will investigate the broad role of factor replacement and raise the question: is trough alone enough to adequately evaluate patient outcomes?

This panel discussion will be followed by a Q&A session. To learn more, contact your Bioverativ® representative or visit the Bioverativ® booth in the THSNA exhibit hall.

Continuing education credits will not be offered for this program.

 

Innovative Product Profiles: Case Studies From the Patients’ and Physicians’ Perspectives

Sponsored By: CSL Behring
12:100 PM - 2:00 PM, Marriott Grand Ballroom 3 & 4

CSL Behring invites you to join in an exciting discussion featuring patients and physicians with compelling treatment journeys. Each case will demonstrate improved health outcomes based on the transition to new therapy.  Their unique stories illustrate examples of successful treatment in the context of surgical application and ongoing management of highly active hemophilia patients. Come and learn the clinical and behavioral characteristics which ultimately influenced the prescribers’ and patients’ decisions.  This interactive panel will conclude with questions and answers from the audience to allow further exploration of the key factors that contributed to their success; both from the patients’ and physicians’ perspectives.

Lunch will be provided. 

 

Introducing myPKFiT™ for ADVATE® [Antihemophilic Factor (Recombinant)]

Sponsored By: Shire US Inc.
6:30 PM - 8:30 PM, Marriott Grand Ballroom 1 & 2

myPKFiT for ADVATE is an FDA-cleared, web-based software that uses individual patient data and a computer algorithm. This session will provide an introduction to myPKFiT for ADVATE and a series of case studies focused on use of myPKFiT for ADVATE. There also will be a panel session for questions and answers.

Please provide your RSVP: https://Shire.cvent.com/d/ntqbpz

 

Friday, March 9th


A Multi-Stakeholder Perspective on a New Subcutaneous Treatment Option for Hemophilia A with FVIII Inhibitors

Sponsored By: Genentech
12:100 PM - 2:00 PM, Marriott Grand Ballroom 1 & 2

This symposium will provide an overview and discussion of emicizumab-kxwh, a newly approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. Topics of discussion will include approved indications, important safety information, key findings from clinical trials, and other important prescribing information. The program will also include a conversation between investigators, healthcare providers, and a patient with hemophilia A with inhibitors who is currently taking emicizumab-kxwh.

The panel discussion will be followed by a question-and-answer session. This program is not offering CME credits.

Program Panelists:

  • Michael Callaghan, MD
  • Doris Quon, MD, PhD
  • Kim Schafer, RN, MSN, FNP
  • Harvey Liverman – our patient guest

 

Changing the paradigm™ of hemophilia B

Sponsored by Novo Nordisk
12:00 PM - 2:00 PM, Marriott Grand Ballroom 3 & 4

Presenters: Dr. Guy Young, MD and Dr. Miguel Escobar, MD

An interactive educational program discussing factor IX activity levels of extended and standard half-life products and maintaining adequate hemostasis. The program will also feature aspects of the paradigm™ clinical trial program and information on a factor IX extended half-life product.

Audience: Designed for health care professionals

Goals: This program will provide attendees with information on the importance of factor IX activity levels and maintaining adequate hemostasis in patients with hemophilia B. In addition, this program will highlight the paradigm™ pivotal clinical trials and PEGylation and provide product information.

Objectives:

  • Discuss the importance of factor IX activity levels and maintaining adequate hemostasis.
  • Provide useful information about an extended half-life factor IX product as an on-demand treatment option for hemophilia B.

Session Topics:

  • Factor IX activity levels
  • The paradigm™ clinical trial program
  • Product information